EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy

E-ISSN： 2212-3970|1|2|209-222

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.1, Iss.2, 2006-06, pp. : 209-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toxicité cutanée des anti-EGF-R

By Ktiouet-Abassi S. Dalle S. Thomas L. Blay J.-Y. Fayette J.

Oncologie, Vol. 8, Iss. 10, 2006-12 ,pp. : 889-894

Springer Publishing Company

Access to resources Recommend Favorite

EGF, TGF-α, and EGF-R in Human Colorectal Adenocarcinoma

By Messa Caterina Russo Francesco Caruso Maria Gabriella Di Leo Alfredo

Acta Oncologica, Vol. 37, Iss. 3, 1998-07 ,pp. : 285-289

Informa Healthcare

Access to resources Recommend Favorite

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

By Van Cutsem Eric

Targeted Oncology, Vol. 3, Iss. 4, 2008-10 ,pp. : 223-225

Springer Publishing Company

Access to resources Recommend Favorite

Serum and Correspondent Tissue Measurements of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGF-R): Clinical Relevance in Pancreatic Cancer and Chronic Pancreatitis

International Journal of Gastrointestinal Cancer, Vol. 25, Iss. 2, 1999-04 ,pp. : 89-96

Humana Press, Inc

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite